Laya Healthcare Directors Receive €12M Pay Increase Amid Premium Hikes

Dónal Clancy, managing director of Laya Healthcare, and other directors received a total of €11.94 million in pay. This amount is six times higher than the €1.9 million paid to directors in 2022.

Seven directors were on the board during the year. Laya Healthcare raised its premiums by an average of 6.5% last month, citing higher demand for healthcare services and increased costs. This increase followed a 7% rise in April and two previous hikes last year.

The rise in director pay contributed to a 75% drop in pre-tax profits, which fell from €36.55 million to €9 million. Revenue decreased by 3%, from €104 million to €100.5 million. Staff costs rose by 17%, increasing from €38.28 million to €44.74 million, with the total number of employees growing from 617 to 664.

What factors contribute to the disparity between executive compensation and company performance at Laya Healthcare?

Interview with Financial Analyst on Laya Healthcare’s Recent Financial Performance and Executive Compensation

Interviewer: We are joined today by [Specialist’s Name], a financial analyst with extensive experience in the healthcare sector. Thank you for joining us to discuss Laya Healthcare’s recent financial disclosures, particularly the alarming rise in executive pay amidst a significant drop in profits.

Specialist: Thank you for having me.

Interviewer: Laya Healthcare recently reported that its managing director, Dónal Clancy, along with other directors, received a staggering total of €11.94 million in pay, which is six times higher than the €1.9 million paid to directors in 2022. What are your thoughts on this increase in compensation?

Specialist: This is a substantial jump in pay, especially considering the context. Executive compensation often reflects performance, but in this case, it seems disconnected from the company’s profitability. With pre-tax profits plummeting 75% from €36.55 million to €9 million, it raises questions about the appropriateness of such increases. Stakeholders might view this as misalignment between executive rewards and company performance, especially as many employees may be facing stagnant or declining wages in the current economic climate.

Interviewer: Indeed, there’s a notable contradiction between soaring director pay and the company’s financial health. Laya also raised its premiums by an average of 6.5% last month, following a series of increases earlier this year. How do you think this will affect customer perception and membership growth?

Specialist: Raising premiums, especially in such a short period, can lead to customer dissatisfaction. While the company justifies these increases by citing higher demand for healthcare services and rising costs, customers may feel they are being asked to pay more while witnessing declining profits and escalating executive pay. On the other hand, they reported an increase in membership to over 696,000, which suggests that despite higher costs, demand for private health insurance remains strong. However, maintaining this growth could become challenging if customers feel the value is not aligned with their costs.

Interviewer: The financial report shows that staff costs also rose significantly by 17%, and the workforce increased from 617 to 664 employees. Given these changes, what do you foresee for the company’s overall financial stability?

Specialist: The increase in staff costs is notable, especially in conjunction with declining revenue, which fell by 3%. This should be carefully monitored, as unsustainable cost structures can lead to longer-term financial difficulties. While increasing the workforce could imply growth or an attempt to enhance service delivery, it also adds to the financial burden. The company must ensure that the increased remuneration for top executives does not come at the expense of its operational capabilities.

Interviewer: with Laya reporting accumulated profits totaling €40.96 million but also observing a significant drop in cash funds by €118.49 million, what implications does this have for the company’s future strategies?

Specialist: The reduction in cash reserves is concerning. The ability to sustain operations, invest in future growth, or navigate unforeseen challenges can be severely hampered if cash funds are dwindling. Consequently, Laya Healthcare may need to adopt a more cautious approach, focusing on cost management and maximizing operational efficiencies. Additionally, transparent communication with members and stakeholders about how the company intends to manage its financial health will be crucial in maintaining trust and credibility in the market.

Interviewer: Thank you, [Specialist’s Name], for your insights into Laya Healthcare’s financial situation. It’s clear that the balance between executive compensation and overall organizational health will be a focal point as we move forward.

Specialist: Thank you for having me. It’s critical for companies, especially in the healthcare sector, to prioritize both performance and the perception of fairness among all stakeholders.

Laya’s membership increased to over 696,000, up from 676,000 the previous year. The company paid €25 million in dividends to its subsidiary, Corebridge Financial, before its sale to Axa, following a previous dividend of €20 million.

The profit figure includes non-cash depreciation costs of €4.8 million. By the end of December, Laya’s accumulated profits totaled €40.96 million. However, the company’s cash funds decreased by €118.49 million to €96.3 million, consisting of €44.29 million in cash balances and €52 million in restricted cash held for the underwriter.